For Grns, that was the product itself
Regular check-ins allow your provider to assess progress, monitor key health metrics, and make any necessary adjustments to ensure your treatment stays effective
The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in adults with overweight or obesity and established heart disease (Lincoff et al., SELECT trial, New England Journal of Medicine , 2023)
Available from: com/intelligence/pages/antiobesity-drug-market.html 8 Erman, M., 2023
doi: 10.1007/s13205-021-02738-3 52 SebastiaoICandeiasESantosMSde OliveiraCRMoreiraPIDuarteAI
and Dorothy R